- Home
- IMRX
as 07-08-2024 4:00pm EST
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 32.3M | IPO Year: | 2021 |
| Target Price: | $15.14 | AVG Volume (30 days): | 370.0K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $11.06 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immuneering Corporation (IMRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $3.07 | 100 | $307.00 | 3,295,173 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $3.07 | 300 | $919.50 | 3,294,873 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $3.05 | 100 | $305.00 | 3,294,773 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $3.03 | 600 | $1,818.00 | 3,294,173 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $3.01 | 10 | $30.10 | 3,294,163 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $2.98 | 10 | $29.80 | 3,294,153 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $2.97 | 280 | $831.60 | 3,293,873 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Apr 1 '24 | Sell | $2.90 | 398,600 | $1,155,940.00 | 2,895,273 | SEC Form 4 |
| Feinberg Peter | IMRX | Director | Mar 22 '24 | Buy | $2.55 | 25,000 | $63,712.50 | 111,766 | SEC Form 4 |
| Brakewood Harold Eugene | IMRX | Chief Business Officer | Mar 22 '24 | Buy | $2.57 | 3,900 | $10,015.20 | 3,900 | SEC Form 4 |
| Schall Thomas J. | IMRX | Director | Mar 22 '24 | Buy | $2.55 | 2,900 | $7,384.85 | 2,900 | SEC Form 4 |
| Zeskind Benjamin J. | IMRX | PRESIDENT AND CEO | Mar 19 '24 | Buy | $2.77 | 20,000 | $55,326.00 | 2,281,852 | SEC Form 4 |
| BERMAN ANN E | IMRX | Director | Mar 18 '24 | Buy | $2.13 | 57,965 | $123,436.47 | 67,465 | SEC Form 4 |
| Feinberg Peter | IMRX | Director | Mar 18 '24 | Buy | $2.31 | 45,024 | $103,856.86 | 56,790 | SEC Form 4 |
| Feinberg Peter | IMRX | Director | Mar 18 '24 | Buy | $3.05 | 4,976 | $15,201.18 | 61,766 | SEC Form 4 |
| Feinberg Peter | IMRX | Director | Mar 18 '24 | Buy | $2.56 | 25,000 | $64,000.00 | 86,766 | SEC Form 4 |
| Morales Mallory | IMRX | Chief Accounting Officer | Mar 15 '24 | Buy | $2.72 | 1,107 | $3,008.72 | 7,885 | SEC Form 4 |
| Morales Mallory | IMRX | Chief Accounting Officer | Mar 15 '24 | Buy | $2.55 | 393 | $1,000.38 | 8,278 | SEC Form 4 |
| Neufeld Leah R | IMRX | CHIEF PEOPLE OFFICER | Mar 15 '24 | Buy | $2.88 | 3,818 | $10,993.17 | 10,029 | SEC Form 4 |
| Hall Brett Matthew | IMRX | CHIEF SCIENTIFIC OFFICER | Mar 15 '24 | Buy | $2.86 | 7,000 | $20,020.00 | 345,896 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Mar 14 '24 | Sell | $3.24 | 345,266 | $1,116,935.51 | 3,859,098 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Mar 14 '24 | Sell | $4.25 | 98,570 | $418,429.65 | 3,760,528 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Mar 14 '24 | Sell | $5.37 | 54,215 | $291,351.41 | 3,706,313 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Mar 14 '24 | Sell | $5.97 | 11,040 | $65,886.72 | 3,695,273 | SEC Form 4 |
| Cormorant Asset Management, LP | IMRX | 10% Owner | Mar 14 '24 | Sell | $2.14 | 400,000 | $856,400.00 | 3,295,273 | SEC Form 4 |
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
Argus Research
20 days ago
Daily – Vickers Top Insider Picks for 06/18/2024
Argus Research
21 days ago
Daily – Vickers Top Insider Picks for 06/17/2024
Argus Research
24 days ago
Daily – Vickers Top Insider Picks for 06/14/2024
Argus Research
25 days ago
Daily – Vickers Top Insider Picks for 06/13/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 06/12/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 06/11/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 06/10/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 06/07/2024
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.